COULD CISPLATIN AS A FRONT-LINE TREATMENT IN CHILDHOOD NON-HODGKIN'S LYMPHOMA BE A PROMISING THERAPY?

Non-Hodgkin's lymphomas (NHL) were often erroneously diagnosed as other malignancies and treated accordingly. In this study cisplatin combined with vincristine, cyclophosphamide, and Adriamycin was used incidentally as a front-line treatment in seven children with NHL, because the initial histo...

Full description

Saved in:
Bibliographic Details
Published inPediatric hematology and oncology Vol. 16; no. 4; pp. 341 - 346
Main Authors Papadopoulou, Athina L., Moschovi, Mary, Panagopoulou-Cristaki, Marili, Anagnostou-Keramida, Dimitra, Vliet-Constantinidou, Catherine Van, Botsonis, Athanasios, Tsangaris, George Th, Tzortzatou-Stathopoulou, Fotini
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Informa UK Ltd 01.07.1999
Taylor & Francis
Subjects
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bone Marrow - drug effects
Child
Child, Preschool
Childhood
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Female
Front-LINE Treatment
Hematologic and hematopoietic diseases
Humans
Ki-1 Lymphoma
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin - drug therapy
Male
Medical sciences
Non-HODGKIN'S Lymphoma
Antineoplastic agent
Evaluation
Chemotherapy
Lymphoproliferative syndrome
Treatment efficiency
Remission
Malignant hemopathy
Non Hodgkin lymphoma
Therapeutic protocol
Cisplatin
Platinum II Complexes
Online AccessGet full text

Cover

More Information
Summary:Non-Hodgkin's lymphomas (NHL) were often erroneously diagnosed as other malignancies and treated accordingly. In this study cisplatin combined with vincristine, cyclophosphamide, and Adriamycin was used incidentally as a front-line treatment in seven children with NHL, because the initial histologic diagnosis was that of a sarcoma. After reevaluation three patients had Ki-1 anaplastic large cell lymphoma of T-cell origin, two abdominal B-cell diffuse high-grade NHL, one mediastinal diffuse large B-cell lymphoma, and one B-cell lymphoma in the stomach. They received at least two courses of cisplatin combined regimen and continued with other protocols for NHL. All patients showed an extremely good response from the first course of therapy and the masses vanished completely. They were followed up for a mean time of 29.5 months and are all in complete remission. The data indicate that cisplatin is active against NHL and might be a promising alternative front-line therapy.
ISSN:0888-0018
1521-0669
DOI:10.1080/088800199277173